Evercore Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60

Evercore維持Moderna(MRNA.US)持有評級，下調目標價至60美元

moomoo資訊 · 10/28 08:31 · 評級/大行評級

Evercore analyst Cory Kasimov maintains $Moderna (MRNA.US)$ with a hold rating, and adjusts the target price from $105 to $60.

According to TipRanks data, the analyst has a success rate of 56.0% and a total average return of 20.0% over the past year.

AnalystRecentRatingAutoNews_76721001012871_20241028_0eb81c3c4154edcff75872a4d9768a16b0d3a4aa_1730136658212908_mm_en

Furthermore, according to the comprehensive report, the opinions of $Moderna (MRNA.US)$'s main analysts recently are as follows:

Moderna's stock performance has been challenged with a 50% decline since the start of the year, amidst uncertainties surrounding future revenues from respiratory vaccines. Nevertheless, there is potential for growth from pipeline programs. The anticipation of cytomegalovirus Phase 3 results by the end of the year is seen as a key driver for the stock's recovery and a significant indicator for the company's wider latent virus portfolio.
After conducting an exhaustive review of the model and considering the guidance reductions announced during R&D Day, along with the projected vaccination trends for Fall 2024, it's evident that investor sentiment remains low. The market's attention is concentrated on the changing dynamics of COVID and RSV, as well as the factors that could potentially lead to a positive shift.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Evercore分析師Cory Kasimov維持$Moderna (MRNA.US)$持有評級，並將目標價從105美元下調至60美元。

根據TipRanks數據顯示，該分析師近一年總勝率為56.0%，總平均回報率為20.0%。

AnalystRecentRatingAutoNews_76721001012871_20241028_0eb81c3c4154edcff75872a4d9768a16b0d3a4aa_1730136658212908_mm_tc

此外，綜合報道，$Moderna (MRNA.US)$近期主要分析師觀點如下：

由於呼吸疫苗未來收入的不確定性，Moderna的股票表現受到挑戰，自年初以來下跌了50％。儘管如此，管道項目仍有增長的潛力。對鉅細胞病毒第三階段業績的預期被視爲該股復甦的關鍵驅動力，也是該公司更廣泛的潛在病毒投資組合的重要指標。
在對該模型進行了詳盡的審查並考慮了研發日期間宣佈的指導削減措施以及2024年秋季的預計疫苗接種趨勢之後，很明顯，投資者的情緒仍然很低。市場的注意力集中在COVID和RSV不斷變化的動態上，以及可能導致積極轉變的因素上。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Evercore Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60

Evercore Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60

風險及免責聲明

聲明